Key result
Flecainide linked to generalized myalgias and weakness that resolve within 24 hours of discontinuation.
Case Report (n=1)
Flecainide can cause rare but reversible myalgias and weakness, which should be considered in patients presenting with these symptoms after initiation of the drug.
Answers are grounded in this paper and cite their sources.
May prompt flecainide consideration in unexplained myalgias; hypothesis-generating case report needing larger confirmation.
Flecainide is a class 1C antiarrhythmic, which is known to cause several cardiac and non-cardiac adverse reactions. We report a case of a 62-year-old woman with atrial fibrillation who presented with generalised myalgias and intermittent chest heaviness after being started on flecainide. She had undergone her third cardiac ablation 1 week prior to presentation and was subsequently started on flecainide 150 mg two times per day. On physical examination, she had diminished reflexes and diffuse calf tenderness. Her blood tests demonstrated an increased erythrocyte sedimentation rate and C reactive protein, but otherwise normal infectious and autoimmune labs. Her ECG showed normal sinus rhythm. A Naranjo score of 7 suggested flecainide as a probable cause of her myalgias. The patient's symptoms started to normalise within 24 hours of discontinuation of flecainide. Our case highlights that myalgias are a potential rare adverse effect that should be considered in patients prescribed flecainide.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2021) conducted a case report in Atrial fibrillation (n=1). Flecainide was evaluated on Myalgias and weakness. Flecainide use in a 62-year-old woman was identified as the probable cause of generalised myalgias and weakness, which resolved within 24 hours of discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: